Last reviewed · How we verify
NCT03938766
Upregulation of PSMA Receptors After Androgen Deprivation Therapy on PSMA PET/CT Imaging in Prostate Cancer
NA trial testing PSMA PET/CT in Prostate Cancer in 2 participants. Completed in 1 February 2020.
1 February 2020
Quick facts
| Lead sponsor | Jewish General Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Design | sequential |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 2 |
| Start date | 2 February 2018 |
| Primary completion | 1 February 2020 |
| Estimated completion | 1 February 2020 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- PSMA PET/CT
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
Sponsor
Jewish General Hospital
Who can join
18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Prostate specific membrane antigen (PSMA) is a unique membrane bound glycoprotein, which is overexpressed on prostate cancer cells and is well-characterized as an imaging biomarker of prostate cancer. Studies have shown that PSMA PET/CT can detect prostate cancer lesions with excellent contrast and a high detection rate even when the level of prostate specific antigen is low. PSMA imaging is considered the gold standard in imaging of biochemical recurrence, with detection rate of recurrence in 79.5% of patients, in the largest series of 1007 patients. Despite these excellent results, there remains approximately 20% of patients in whom the site of biochemical recurrence cannot be identified and further research is needed into improving detection rates. Androgen deprivation therapy (ADT), represents the standard of care treatment for most men with a rising serum PSA and no evidence of disseminated disease on imaging modalities. There has been some preliminary data that imaging patients early after initiation of ADT therapy may increase detection rates of recurrence sites. The objective of this study is to evaluate if prostate cancer patients with biochemical recurrence and negative PSMA PET/CT can demonstrate in-vivo upregulation of PSMA receptors in an attempt to improve detection rates of recurrent prostate cancer. Patients who are started on ADT when clinically indicated, will have repeat PSMA PET/CT at 4 weeks following initiation of ADT therapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03938766
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PSMA PET/CT
Trials testing the same drug.
- NCT06387238 — Exploration of the Value of PSMA PET/CT in Dynamic Monitoring of the Efficacy of Novel Endocrine Therapy in Patients Wit · NA · not yet recruiting
- NCT06209853 — Correlation Between PSA Levels and F-18 PSMA PET/CT Findings in Prostate Cancer Patient · recruiting
- NCT04745871 — Diagnostic Performance of PSMA PET/CT for Pre-operative Lymph Node Assessment in Intermediate and High-risk Non-metastas · NA · recruiting
- NCT04298112 — PSMA-PET and MRI for Detection of Recurrent Prostate Cancer After Radical Treatment · completed
- NCT03841760 — SUV on PSMA PET/CT in Non-Prostate Tumors · Phase 2 · terminated
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other Jewish General Hospital trials
Trials by the same sponsor.
- NCT05188222 — Preoperative Maltodextrin's Effect on Cardiac Function in Cardiac Surgery · Phase 4 · not yet recruiting
- NCT06701929 — The Impact of Fasting Duration on Quality of Recovery After Cesarean Section · recruiting
- NCT05719415 — Functional Pulmonary Capillary Surface Area in BPA for CTEPH · NA · recruiting
- NCT04678986 — ER2 and Deep Learning for Prediction of Adverse Health Outcomes · withdrawn
- NCT04893876 — The OPERa Study: Evaluating QoL After Rectal Cancer Surgery · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03938766 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jewish General Hospital
- Last refreshed: 12 February 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03938766.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing